ArticleJournal of controlled release : official journal of the Controlled Release Society2017
Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Preclinical efficacy of drug delivery systems in colon cancer therapy: a systematic review and meta-analysis of in vivo animal studies.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Overcoming colorectal cancer and cancer stem cell resistance with photodynamic therapy: new frontiers in oncology.RSC advances · 2025Review
- Therapeutic Supramolecular Polymers: Designs and Applications.Progress in polymer science · 2024Article
- Photodynamic Therapy for Colorectal Cancer: An Update and a Look to the Future.International journal of molecular sciences · 2023Review
- Current Challenges and Opportunities of Photodynamic Therapy against Cancer.Pharmaceutics · 2023Review
- Stimuli-responsive crosslinked nanomedicine for cancer treatment.Exploration (Beijing, China) · 2022Review
- Novel pH-Responsive Cubosome and Hexosome Lipid Nanocarriers of SN-38 Are Prospective for Cancer Therapy.Pharmaceutics · 2022Article
- Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer.Journal of nanobiotechnology · 2022Review
- Review
- Folate Decorated Multifunctional Biodegradable Nanoparticles for Gastric Carcinoma Active Targeting Theranostics.International journal of nanomedicine · 2022Article
- Porphyrin/Chlorin Derivatives as Promising Molecules for Therapy of Colorectal Cancer.Molecules (Basel, Switzerland) · 2021Review
- Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.Acta biomaterialia · 2021Article
- A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors.Biomaterials · 2020Article
- Developments of Smart Drug-Delivery Systems Based on Magnetic Molecularly Imprinted Polymers for Targeted Cancer Therapy: A Short Review.Pharmaceutics · 2020Review
- Photothermal therapy technology of metastatic colorectal cancer.American journal of translational research · 2020Review
- Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations.PloS one · 2019Article
- A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging.Nanoscale · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
The tumor penetration and accumulation of nanoparticle-based drug delivery systems are highly dependent on the particle size. Nanomedicines in the sub-100nm range have been suggested by previous studies to have superior antitumor efficacy on various solid tumors. SN-38 is a very important and highly potent drug for several cancers including colon cancer. However, due to the ultra-flat aromatic structure of SN-38, it is typically very difficult to produce sub-100nm, SN-38-encapsulated nanoparticles without modification of the chemical structure. Here, we report on the successful production of 20-30nm, SN-38-encapsulated photonic micelles for effectively trimodal cancer therapy. Taking advantages of the supramolecular "π-π" stacking and hydrophobicity interaction between SN-38, and a unique class of photonic nanoporphyrin micelles (NPM), the extremely hydrophobic SN-38 was successfully encapsulated into NPM with significantly increased water solubility (up to 500 times). At equivalent dose of drug, photosensitizer and light irradiation, combination therapy with SN-38-encapsulated nanoporphyrin micelles (SN-NPM) enhanced the in vitro antitumor activity by 78 and 350 times over single treatment with SN-38 and phototherapy alone, respectively. Due to the relatively small size, SN-NPM possessed superior long tumor retention time (>5days) and much higher accumulation in tumors than in normal organs, as shown by near-infrared fluorescence (NIRF) imaging. Furthermore, the trimodal therapy (photothermal-, photodynamic- and chemo-therapy) with SN-NPM demonstrated dramatically enhanced in vivo antitumor efficacy over single treatment on nude mice bearing HT-29 colon cancer xenograft. Therefore, these sub-100nm, SN-38-encapsulated photonic micelles show great promise for multimodal cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.